Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Wall Street analysts reasoned out why Pfizer (NYSE:PFE) shares could be under pressure on Tuesday even as the New York-based ...

Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, ...

That's impressive when you consider that Pfizer has experienced significant declines in COVID-19-related drug sales. Revenue ...

During the COVID pandemic's height, for example, Pfizer was not only the co-developer of the widely distributed Comirnaty vaccine, it was also the entity behind the go-to drug therapy Paxlovid.

Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.